← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Faknostics, Llc
Phoenix, AZ
$4,916,357
Total funding
5
Grants
Funding over time
peak $1.3M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,916,357 · 5
By mechanism
R42$4,326,858 · 3
R41$589,499 · 2
Investigators at Faknostics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$674,537
R42 · FY2021 · CA
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$673,796
R42 · FY2024 · HL
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$670,756
R42 · FY2022 · CA
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$663,777
R42 · FY2025 · DK
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$663,310
R42 · FY2025 · HL
Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma$654,706
R42 · FY2023 · CA
Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis$325,976
R42 · FY2024 · DK
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis$299,905
R41 · FY2022 · HL
Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK)$289,594
R41 · FY2019 · CA